Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average) (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $257.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 21.91% to $257.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $257.2 million through Dec 2025, up 21.91% year-over-year, with the annual reading at $257.2 million for FY2025, 21.91% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $257.2 million at Akebia Therapeutics, down from $264.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $264.8 million in Q3 2025, with the low at $153.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $197.6 million, with a median of $186.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 1.75% in 2023, then increased 27.09% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $165.9 million in 2021, then increased by 10.14% to $182.8 million in 2022, then increased by 2.56% to $187.5 million in 2023, then increased by 12.53% to $210.9 million in 2024, then increased by 21.91% to $257.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $257.2 million, $264.8 million, and $249.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.